How to cite: Gipp, I. “Driving Broader Impact: The Emerging Role of Radio-Ligand Therapies.” September 15, 2025. Accessed Oct 2026. https://grandroundsinurology.com/driving-broader-impact-the-emerging-role-of-radio-ligand-therapies/
Summary
Ilya Gipp, MD, PhD, Chief Medical Officer, GE Healthcare, Atlanta, Georgia, highlights current opportunities and challenges in radioligand therapy for prostate cancer. He emphasizes the role of prostate-specific membrane antigen (PSMA) in enabling radiotheranostics, explaining that PSMA-targeted imaging provides a foundation for both diagnosis and therapy when paired with therapeutic isotopes like lutetium.
Dr. Gipp shares that radioligand therapy has demonstrated notable responses in metastatic castration-resistant prostate cancer. However, up to 50 percent of patients receiving lutetium-PSMA may not achieve prostate-specific antigen (PSA) responses, underlining the need for improved prediction and patient selection. He noted the increasing relevance of outcomes-based agreements, designed to link reimbursement and access to patient benefit, which may shape future clinical practice.
Dr. Gipp stresses that radioligand therapy must be tailored to each individual. Heterogeneity in tumor distribution and uptake affects outcomes, making uniform treatment activity insufficient. He highlights evidence showing a decrease in absorbed doses across treatment cycles, supporting the need for predictive planning rather than reactive management.
He further described emerging strategies, including the use of alpha emitters, varied molecular vehicles, new conjugates, and treatment combinations with radiation or chemotherapy. These developments generate numerous potential therapeutic approaches, underscoring the need for collaboration through knowledge sharing and interdisciplinary dialogue.
Dr. Gipp asserts that the broader impact of radioligand therapy depends on embracing data-driven personalization, predictive modeling, partnerships, and integration of artificial intelligence to enhance patient selection, delivery, monitoring, and follow-up.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical cases and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Ilya Gipp, MD, PhD is Chief Medical Officer, Oncology at GE Healthcare in Atlanta, Georgia. Dr. Gipp leads the development and execution of the medical and clinical strategy for cancer care solutions. His focus is on the clinical, organizational, financial, and population health dimensions of breast, prostate, lung, colorectal, liver, head and neck, and other cancers. Dr. Gipp guides the clinical aspects of market strategy, product development, solution design, and implementation across GE HealthCare’s Oncology Pathways field.
